Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Should be a good week for PRED - hammer time
$ABLM$ yes excellent commitment.That’s the entire $10 M -money could hit the wire in a few days as it will come in tranches
Over 2 months without an update - news must be close
$ABML$ Gap filled - let’s roll
They are a long way from Nasdaq. Keeping QB was important but these jokers can’t be trusted till they prove themselves. I see big time up side near term - just can’t forget how poorly managed this company has been.
Time to sell was 6 months ago. Now is the time to buy the blood. Company has a billion in assets and top partners around the world. The stock will sell off and get bought up big time
PRED is worth $5 on a fire sale. Stem cell
Biz is a small part of their value.
AXIM Biotechnologies, Inc. (AXIM: OTCQB) PLATINUM SPONSOR
John W Huemoeller II
About AXIM® Biotechnologies
Founded in 2014, AXIM® Biotechnologies, Inc. (AXIM) is a world leader in the research and development of plant and laboratory-derived cannabinoid and oncological therapeutics. AXIM's proprietary research intends to find new ways to diagnose and treat cancer as well as other conditions, such as the intense side effects of chemotherapy, through innovative pharmaceutical delivery systems, cannabinoid-based active pharmaceutical ingredients, and novel therapeutics.
Currently, AXIM is undergoing clinical studies to its cannabinoid pharmaceutical product, MedChew® with dronabinol and acquiree Sapphire Biotech, Inc.’s diagnostic tool is being used to study the company's enzyme biomarker to detect pancreatic cancer earlier than circulating tumor cells. Learn more here. For more information, please visit www.AXIMBiotech.com.
$AXIM
AXIM Biotechnologies, Inc. (AXIM: OTCQB) PLATINUM SPONSOR
John W Huemoeller II
About AXIM® Biotechnologies
Founded in 2014, AXIM® Biotechnologies, Inc. (AXIM) is a world leader in the research and development of plant and laboratory-derived cannabinoid and oncological therapeutics. AXIM's proprietary research intends to find new ways to diagnose and treat cancer as well as other conditions, such as the intense side effects of chemotherapy, through innovative pharmaceutical delivery systems, cannabinoid-based active pharmaceutical ingredients, and novel therapeutics.
Currently, AXIM is undergoing clinical studies to its cannabinoid pharmaceutical product, MedChew® with dronabinol and acquiree Sapphire Biotech, Inc.’s diagnostic tool is being used to study the company's enzyme biomarker to detect pancreatic cancer earlier than circulating tumor cells. Learn more here. For more information, please visit www.AXIMBiotech.com.
I’ll be doubling my position this week. These guys guys aren’t going away. Incredible value in their data base diagnostics and patents
They have to do something - stock has gotten destroyed
Maybe brad will buy 10,000 - big spender
meant for nasdaq to get out of this pink cess pool
why dont they just do an R/S and put us out of misery
Been brutal holding this stock for a year.
How does that $100M funder @ $5.40 feel about the pps
CTO Ryan Melsert was the keynote speaker at an IEA conference in Paris - he’s considered a world leading industry expert in electrochemistry and clean tech
https://finance.yahoo.com/news/american-battery-metals-corporations-chief-133000708.html
TSLA buyout after Musk realizes his let his high tech battery wiz Melsert leave with revolutionary recycling tech. ABML is a few miles away from the Tesla battery giga factory. BASF stopped their recycling research after seeing Melsert's presentation. 9 BASF executives were in Boston at Greentech.
Excellent news - it’s coming and so is a big pop in pps
Wow - what’s up with that?
Prove the efficacy of the product then commercialize - market is worth billions
Excellent news - ARTguide is better then expected for fertility diagnostics
They also are trialing ARTguide in a CT clinic as well per an email from the company
PRED is Pathetic
$AMBL$ up on high volume. Funding must be close
Need a green close and bottom
50 and 200 are at @.25 - could have a golden cross it this turns back up
Management gent sucks - they hate investors but news is coming - the psoriasis cream has billion dollar potential and heading to phase 2
Added @.31 - oversold great potential
Activist short selling has been on the rise in Canadian markets in the past few years, with some prominent short sellers using social media outlets such as Twitter to publicize their positions and amplify their views. This has added a new dimension to the friction between investors seeking growth and those who borrow shares in a bet the price will fall so they can profit from the difference when they return the shares.
Will also launch project into cannabis, crypto promotions 'unbalanced to such extent that they may mislead investors': CSA
Canada’s securities watchdogs are teaming up to determine whether and how much “abusive” short selling is taking place in the country’s capital markets.
The Canadian Securities Administrators, an umbrella organization that coordinates the activities of Canada’s 13 provincial and territorial market watchdogs, is in the preliminary stages of a project that involves reviewing “the nature and extent of abusive short-selling in Canadian capital markets,” Brian Kladko, a public affairs manager at the British Columbia Securities Commission, said Thursday.
“We are in the information-gathering phase of this initiative,” he said in an interview, speaking on behalf of the CSA.
His comments followed the publication of a CSA notice on a separate topic: problematic promotional activities by companies. While that report was concerned with promotional campaigns that “appear to be undertaken for the specific purpose of artificially promoting interest” in the companies’ securities, the CSA said it was planning a separate project to analyze the impact of activist short sellers on Canada’s capital markets.
The regulators declined to comment further Thursday on whether their focus on short selling will be on trading rules, communications, or some other aspect of short campaigns.
They were clearer on their response to “problematic” promotional activities they are seeing in emerging sectors such as cryptocurrency, cannabis, and block-chain, as well as mining.
In Thursday’s notice, the CSA warned that its concerns extend beyond the venture marketplace and may result in a regulatory response ranging from requiring a company to issue a “clarifying” news release to referring the matter to enforcement.
“We will continue to monitor promotional activity and we will consider whether the scope and extent of problematic promotional activities require compliance or enforcement regulatory action to protect investors and the integrity of our capital markets,” the regulatory organization said in the notice.
The CSA is particularly concerned about promotional activities regulators have observed that are either untrue or are “unbalanced to such extent that they may mislead investors.”
The regulators did not name any names in connection with the troubling promotional activities, though they did elaborate on specific instances. Among them were cases where a company announces a name or business change that references an association with the cannabis sector or a hot emerging technology or mineral — such as blockchain or cobalt —without a supporting business plan.
There have also been instances where a positive event such as a large acquisition is announced and then the transaction is changed or cancelled without an announcement, and others where numerous news releases are issued that do not disclose any new material facts.
In another iteration of the trend that regulators find concerning, and which they say has the potential to mislead, third parties are compensated to use social media and investing blogs to promote companies without disclosing their compensation or financial interest.
Social media use is an area of increasing focus for regulators, and the CSA is also zeroing in on social media posts that describe early-stage plans with “unwarranted certainty” or make unsupported assertions about the growth of markets or demand for a certain product.
https://business.financialpost.com/news/fp-street/canadian-regulators-put-companies-on-notice-over-problematic-promotions-in-sectors-such-as-cannabis-cryptocurrency
Not sure
Black rock 5.8% stake
Thanks Brian - for all the great DD
Crazy drop - $6 to $4.49 after $100M
Cash infusion at 5.40
Is ARTguide I’m more then 2 clinics in Houston and New Haven
So far worst investment I’ve ever made.
2-3 weeks wait for what?
Shorts want this under the 50 DMA and they are winning
Please elaborate how they will go to NAS this month
So much manipulation— needs nasdaq badly
Successful DD From a world renown professor who offers a collaborative postdoc research position working with Atrin and UPENN
Oren Gilad, Ph.D., president and chief executive officer of Atrin Pharmaceuticals, noted: “Following a successful due diligence process, we concluded that Predictive, with its proprietary list of already identified genes and state-of-the-art sequencing capabilities, is the ideal molecular diagnostic partner to help us successfully advance our therapeutic pipeline through clinical development. We believe that this collaboration may become a ‘game changer’ in oncology, as treatment continues to progress towards individualized precision medicine.